Takeda Pharmaceutical Co Ltd (4502)

Track

Takeda Pharmaceutical experienced significant insider trading activity recently, with fourteen proposed sales totaling approximately 9.86 million dollars. Key executives, including the CEO and R&D President, offloaded shares during July 2026. These divestments represent the entirety of recorded transactions over the past ninety days, occurring without any corresponding open-market purchases by leadership.

No insider activity signal

Not featured in screeners

Featured in screeners

No insider activity signal

Not featured in screeners

Ticker: 4502 Exchange: TYO

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings

Insider activity signals

0 activity signals detected for Takeda Pharmaceutical Co Ltd

No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

Proposed sale 7 Aug 2026

Value US$2,275,323.42 | Price 215.76 | Shares 53,215

Proposed sale 13 Jul 2026

Value US$1,143,231.56 | Price 117.12 | Shares 899

Proposed sale 13 Jul 2026

Value US$416,850.49 | Price 16.75 | Shares 24,887

Proposed sale 13 Jul 2026

Value US$123,072.06 | Price 16.75 | Shares 7,348

Proposed sale 13 Jul 2026

Value US$3,002,257.72 | Price 16.75 | Shares 179,239

Proposed sale 13 Jul 2026

Value US$455,544.81 | Price 16.75 | Shares 27,197

Proposed sale 13 Jul 2026

Value US$1,617,344.29 | Price 16.75 | Shares 96,558

Proposed sale 13 Jul 2026

Value US$564,406.02 | Price 16.75 | Shares 33,696

Proposed sale 13 Jul 2026

Value US$72,351.26 | Price 16.75 | Shares 4,319

Proposed sale 13 Jul 2026

Value US$560,351.40 | Price 16.75 | Shares 33,454

Proposed sale 13 Jul 2026

Value US$863,947.36 | Price 16.75 | Shares 51,579

Proposed sale 13 Jul 2026

Value US$254,398.88 | Price 16.75 | Shares 15,188

Proposed sale 13 Jul 2026

Value US$306,789.10 | Price 16.75 | Shares 18,316

Proposed sale 13 Jul 2026

Value US$132,148.97 | Price 16.75 | Shares 7,889

Proposed sale 9 Dec 2025

Value US$421,182.18 | Price 14.22 | Shares 29,619

Proposed sale 5 Dec 2025

Value US$1,242,688.44 | Price 14.28 | Shares 87,023

Proposed sale 4 Dec 2025

Value US$836,004.51 | Price 14.31 | Shares 58,421

Proposed sale 9 Jul 2025

Value US$537,494.94 | Price 15.42 | Shares 34,857

Proposed sale 9 Jul 2025

Value US$86,475.36 | Price 15.42 | Shares 5,608

Proposed sale 9 Jul 2025

Value US$69,035.34 | Price 15.42 | Shares 4,477

Proposed sale 9 Jul 2025

Value US$287,151.24 | Price 15.42 | Shares 18,622

Proposed sale 9 Jul 2025

Value US$414,397.08 | Price 15.42 | Shares 26,874

Proposed sale 9 Jul 2025

Value US$630,970.98 | Price 15.42 | Shares 40,919

Proposed sale 9 Jul 2025

Value US$94,617.12 | Price 15.42 | Shares 6,136

Proposed sale 9 Jul 2025

Value US$902,979.78 | Price 15.42 | Shares 58,559

Proposed sale 9 Jul 2025

Value US$2,610,806.46 | Price 15.42 | Shares 169,313

Proposed sale 9 Jul 2025

Value US$440,271.84 | Price 15.42 | Shares 28,552

Proposed sale 9 Jul 2025

Value US$811,847.58 | Price 15.42 | Shares 52,649

Proposed sale 9 Jul 2025

Value US$1,587,828.24 | Price 15.42 | Shares 102,972

Proposed sale 23 Aug 2024

Value US$284,950.62 | Price 14.94 | Shares 19,073

Proposed sale 11 Jul 2024

Value US$59,744.94 | Price 13.18 | Shares 4,533

Proposed sale 11 Jul 2024

Value US$507,153.22 | Price 13.18 | Shares 38,479

Proposed sale 11 Jul 2024

Value US$983,939.72 | Price 13.18 | Shares 74,654

Proposed sale 11 Jul 2024

Value US$140,683.32 | Price 13.18 | Shares 10,674

Proposed sale 11 Jul 2024

Value US$363,807.54 | Price 13.18 | Shares 27,603

Proposed sale 11 Jul 2024

Value US$490,546.42 | Price 13.18 | Shares 37,219

Proposed sale 11 Jul 2024

Value US$273,102.78 | Price 13.18 | Shares 20,721

Proposed sale 11 Jul 2024

Value US$80,819.76 | Price 13.18 | Shares 6,132

Proposed sale 11 Jul 2024

Value US$60,786.16 | Price 13.18 | Shares 4,612

Proposed sale 11 Jul 2024

Value US$196,250.20 | Price 13.18 | Shares 14,890

Proposed sale 11 Jul 2024

Value US$1,596,427.50 | Price 13.18 | Shares 121,125

Proposed sale 11 Jul 2024

Value US$79,712.64 | Price 13.18 | Shares 6,048

Proposed sale 11 Jul 2023

Value US$74,133.84 | Price 15.48 | Shares 4,789

Proposed sale 11 Jul 2023

Value US$718,644.64 | Price 15.48 | Shares 46,424

Proposed sale 11 Jul 2023

Value US$1,055,490.39 | Price 15.48 | Shares 68,184

Proposed sale 11 Jul 2023

Value US$31,654.34 | Price 15.48 | Shares 2,045

Proposed sale 11 Jul 2023

Value US$162,873.72 | Price 15.48 | Shares 10,522

Proposed sale 11 Jul 2023

Value US$166,130.52 | Price 15.48 | Shares 10,732

Proposed sale 11 Jul 2023

Value US$455,154.26 | Price 15.48 | Shares 29,403

Proposed sale 11 Jul 2023

Value US$377,620.01 | Price 15.48 | Shares 24,394

Proposed sale 11 Jul 2023

Value US$480,888.97 | Price 15.48 | Shares 31,065

Proposed sale 11 Jul 2023

Value US$2,140,334.39 | Price 15.48 | Shares 138,264

Proposed sale 11 Jul 2023

Value US$146,076.06 | Price 15.48 | Shares 9,436

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2026-08-06	2026-08-07	PrS Proposed sale	Nicola Greenway Chief Human Resources Officer Officer	53,215 215.76 US$2,275,323	53,215	215.76	US$2,275,323
2026-07-13	2026-07-13	PrS Proposed sale	Teresa Bitetti President, Global Oncology Business Unit	899 117.12 US$1,143,232	899	117.12	US$1,143,232
2026-07-13	2026-07-13	PrS Proposed sale	Marcello Pignagnoli Agosti Interim Head, Strategy and Portfolio Development	11,614 65.63 US$4,860,216	11,614	65.63	US$4,860,216
2026-07-13	2026-07-13	PrS Proposed sale	Nicola Greenway Chief Human Resources Officer Officer	7,348 16.75 US$123,072	7,348	16.75	US$123,072
2026-07-13	2026-07-13	PrS Proposed sale	Andrew Plump President, Research & Development	179,239 16.75 US$3,002,258	179,239	16.75	US$3,002,258
2026-07-13	2026-07-13	PrS Proposed sale	Gabriele Ricci Chief Data & Technology Officer Officer	27,197 16.75 US$455,545	27,197	16.75	US$455,545
2026-07-13	2026-07-13	PrS Proposed sale	Julie Kim President and CEO	96,558 16.75 US$1,617,344	96,558	16.75	US$1,617,344
2026-07-13	2026-07-13	PrS Proposed sale	Giles Platford President, International Business Unit	33,696 16.75 US$564,406	33,696	16.75	US$564,406
2026-07-13	2026-07-13	PrS Proposed sale	Elaine Shannon President, Global Supply & Quality	4,319 16.75 US$72,351	4,319	16.75	US$72,351
2026-07-13	2026-07-13	PrS Proposed sale	Natalie Furney Global General Counsel	33,454 16.75 US$560,351	33,454	16.75	US$560,351
2026-07-13	2026-07-13	PrS Proposed sale	Lauren Rusckowski Duprey Chief Transformation Officer Officer	51,579 16.75 US$863,947	51,579	16.75	US$863,947
2026-07-13	2026-07-13	PrS Proposed sale	Awny Farajallah Chief Medical Officer Officer	15,188 16.75 US$254,399	15,188	16.75	US$254,399
2026-07-13	2026-07-13	PrS Proposed sale	Rhonda Pacheco President, US Business Unit and US Country Head	18,316 16.75 US$306,789	18,316	16.75	US$306,789
2026-07-13	2026-07-13	PrS Proposed sale	Ramy Riad President, Plasma-Derived Therapies Business Unit	7,889 16.75 US$132,149	7,889	16.75	US$132,149
2025-12-09	2025-12-09	PrS Proposed sale	Lauren Rusckowski Duprey Chief Human Resources Officer Officer	29,619 14.22 US$421,182	29,619	14.22	US$421,182
2025-12-05	2025-12-05	PrS Proposed sale	Teresa Marie Bitetti President, Global Oncology Business Unit	87,023 14.28 US$1,242,688	87,023	14.28	US$1,242,688
2025-12-04	2025-12-04	PrS Proposed sale	Giles Richard Platford President, Plasma-Derived Therapies Business Unit	58,421 14.31 US$836,005	58,421	14.31	US$836,005
2025-07-09	2025-07-09	PrS Proposed sale	Christophe Pierre Weber Chief Executive Officer Officer	34,857 15.42 US$537,495	34,857	15.42	US$537,495
2025-07-09	2025-07-09	PrS Proposed sale	Akiko Amakawa Corporate Strategy Officer & CEO Chief of Staff Officer	5,608 15.42 US$86,475	5,608	15.42	US$86,475
2025-07-09	2025-07-09	PrS Proposed sale	Elaine Mary Shannon Global Quality Officer Officer	4,477 15.42 US$69,035	4,477	15.42	US$69,035
2025-07-09	2025-07-09	PrS Proposed sale	Marcello Pignagnoli Agosti Global Business Development Officer Officer	18,622 15.42 US$287,151	18,622	15.42	US$287,151
2025-07-09	2025-07-09	PrS Proposed sale	Gabriele Ricci Chief Data & Technology Officer Officer	26,874 15.42 US$414,397	26,874	15.42	US$414,397
2025-07-09	2025-07-09	PrS Proposed sale	Lauren Rusckowski Duprey Chief Human Resources Officer Officer	40,919 15.42 US$630,971	40,919	15.42	US$630,971
2025-07-09	2025-07-09	PrS Proposed sale	Thomas Wozniewski Global Manufacturing & Supply Officer Officer	6,136 15.42 US$94,617	6,136	15.42	US$94,617
2025-07-09	2025-07-09	PrS Proposed sale	Julie Kim President, US Business Unit	58,559 15.42 US$902,980	58,559	15.42	US$902,980
2025-07-09	2025-07-09	PrS Proposed sale	Andrew Plump President, Research & Development	169,313 15.42 US$2,610,806	169,313	15.42	US$2,610,806
2025-07-09	2025-07-09	PrS Proposed sale	Giles Richard Platford President, Plasma-Derived Therapies Business Unit	28,552 15.42 US$440,272	28,552	15.42	US$440,272
2025-07-09	2025-07-09	PrS Proposed sale	Teresa Marie Bitetti President, Global Oncology Business Unit	52,649 15.42 US$811,848	52,649	15.42	US$811,848
2025-07-09	2025-07-09	PrS Proposed sale	Ramona A Sequeira President, Global Portfolio Division	102,972 15.42 US$1,587,828	102,972	15.42	US$1,587,828
2024-08-22	2024-08-23	PrS Proposed sale	Giles Richard Platford President, Plasma-Derived Therapies Business Unit	19,073 14.94 US$284,951	19,073	14.94	US$284,951
2024-07-10	2024-07-11	PrS Proposed sale	Thomas Wozniewski Global Manufacturing & Supply Officer Officer	4,533 13.18 US$59,745	4,533	13.18	US$59,745
2024-07-10	2024-07-11	PrS Proposed sale	Teresa Marie Bitetti President, Global Oncology Business Unit	38,479 13.18 US$507,153	38,479	13.18	US$507,153
2024-07-10	2024-07-11	PrS Proposed sale	Ramona A Sequeira President, Global Portfolio Division	74,654 13.18 US$983,940	74,654	13.18	US$983,940
2024-07-10	2024-07-11	PrS Proposed sale	Marcello Pignagnoli Agosti Global Business Development Officer Officer	10,674 13.18 US$140,683	10,674	13.18	US$140,683
2024-07-10	2024-07-11	PrS Proposed sale	Lauren Rusckowski Duprey Chief Human Resources Officer Officer	27,603 13.18 US$363,808	27,603	13.18	US$363,808
2024-07-10	2024-07-11	PrS Proposed sale	Julie Kim President, US Business Unit	37,219 13.18 US$490,546	37,219	13.18	US$490,546
2024-07-10	2024-07-11	PrS Proposed sale	Giles Richard Platford President, Plasma-Derived Therapies Business Unit	20,721 13.18 US$273,103	20,721	13.18	US$273,103
2024-07-10	2024-07-11	PrS Proposed sale	Gabriele Ricci Chief Data & Technology Officer Officer	6,132 13.18 US$80,820	6,132	13.18	US$80,820
2024-07-10	2024-07-11	PrS Proposed sale	Elaine Mary Shannon Global Quality Officer Officer	4,612 13.18 US$60,786	4,612	13.18	US$60,786
2024-07-10	2024-07-11	PrS Proposed sale	Christophe Pierre Weber Chief Executive Officer Officer	14,890 13.18 US$196,250	14,890	13.18	US$196,250
2024-07-10	2024-07-11	PrS Proposed sale	Andrew Plump President, Research & Development	121,125 13.18 US$1,596,428	121,125	13.18	US$1,596,428
2024-07-10	2024-07-11	PrS Proposed sale	Akiko Amakawa Corporate Strategy Officer & CEO Chief of Staff Officer	6,048 13.18 US$79,713	6,048	13.18	US$79,713
2023-07-10	2023-07-11	PrS Proposed sale	Thomas Wozniewski Global Manufacturing & Supply Officer Officer	4,789 15.48 US$74,134	4,789	15.48	US$74,134
2023-07-10	2023-07-11	PrS Proposed sale	Teresa Marie Bitetti President, Global Oncology Business Unit	46,424 15.48 US$718,645	46,424	15.48	US$718,645
2023-07-10	2023-07-11	PrS Proposed sale	Ramona A Sequeira President, Global Portfolio Division	68,184 15.48 US$1,055,490	68,184	15.48	US$1,055,490
2023-07-10	2023-07-11	PrS Proposed sale	Mwana Lugogo Chief Ethics & Compliance Officer Officer	2,045 15.48 US$31,654	2,045	15.48	US$31,654
2023-07-10	2023-07-11	PrS Proposed sale	Marcello Pignagnoli Agosti Global Business Development Officer Officer	10,522 15.48 US$162,874	10,522	15.48	US$162,874
2023-07-10	2023-07-11	PrS Proposed sale	Lauren Duprey Chief Human Resources Officer Officer	10,732 15.48 US$166,131	10,732	15.48	US$166,131
2023-07-10	2023-07-11	PrS Proposed sale	Julie Kim President, US Business Unit	29,403 15.48 US$455,154	29,403	15.48	US$455,154
2023-07-10	2023-07-11	PrS Proposed sale	Giles Richard Platford President, Plasma-Derived Therapies Business Unit	24,394 15.48 US$377,620	24,394	15.48	US$377,620
2023-07-10	2023-07-11	PrS Proposed sale	Gerard M Greco Global Quality Officer Officer	31,065 15.48 US$480,889	31,065	15.48	US$480,889
2023-07-10	2023-07-11	PrS Proposed sale	Andrew Plump President, Research & Development	138,264 15.48 US$2,140,334	138,264	15.48	US$2,140,334
2023-07-10	2023-07-11	PrS Proposed sale	Gabriele Ricci Chief Data & Technology Officer Officer	9,436 15.48 US$146,076	9,436	15.48	US$146,076

Explore more

More insider trading research around Takeda Pharmaceutical Co Ltd

More insider trades in JP

Similar Healthcare companies with insider activity

More Pharmaceuticals & Medical Research companies with insider activity

More Pharmaceuticals companies with insider activity

Takeda Pharmaceutical Co Ltd (4502)

Track

Featured in screeners

No insider activity signals detected

Transactions

Insider

Sort by

Trades

Explore more